SCHEMBL6495667

SCHEMBL6495667

CCc1nc(-c2ccc(Cl)cc2Cl)c(=O)n(CC)c1N[C@@H]1c2ccccc2C[C@@H]1OC(C)=O

nearest known ligand 0.45

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CRHR1 P34998 16/20 0.45
CNR1 P21554 3/20 0.36
OPRL1 P41146 1/20 0.34
CNR2 P34972 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6495676 1.00 CRHR1 (0.45) CRHR1CNR1OPRL1CNR2
SCHEMBL5782826 1.00 CRHR1 (0.45) CRHR1CNR1OPRL1CNR2
SCHEMBL5780328 0.92 CRHR1 (0.43) CRHR1
SCHEMBL5780326 0.92 CRHR1 (0.43) CRHR1
SCHEMBL6505605 0.92 CRHR1 (0.43) CRHR1
SCHEMBL5785470 0.92 CRHR1 (0.42) CRHR1CNR1OPRL1CNR2
SCHEMBL6506650 0.92 CRHR1 (0.42) CRHR1CNR1OPRL1CNR2
SCHEMBL5783659 0.92 CRHR1 (0.45) CRHR1CNR1CNR2
SCHEMBL6505598 0.92 CRHR1 (0.45) CRHR1CNR1CNR2
SCHEMBL5785473 0.92 CRHR1 (0.42) CRHR1CNR1OPRL1CNR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20050020601-A1 Novel pyrazinones as CRF1 receptor antagonists PFIZER INC 2005-01-27 US claimed
US-20050020601-A1 Novel pyrazinones as CRF1 receptor antagonists PFIZER INC 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020601-A1 Novel pyrazinones as CRF1 receptor antagonists CRHR1, CRHR2, CRH CRHR1 1/4885CNR1 12/4885OPRL1 28/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.